Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.9076
-0.0103 (-1.12%)
At close: Apr 1, 2025, 4:00 PM
0.9000
-0.0076 (-0.84%)
After-hours: Apr 1, 2025, 5:42 PM EDT
Clearside Biomedical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Clearside Biomedical stock have an average target of 5.20, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 472.94% from the current stock price of 0.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Clearside Biomedical stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +561.08% | Mar 31, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +450.90% | Mar 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +561.08% | Mar 28, 2025 |
| Needham | Needham | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +340.72% | Mar 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +561.08% | Mar 6, 2025 |
Financial Forecast
Revenue This Year
2.84M
from 1.66M
Increased by 70.73%
Revenue Next Year
11.13M
from 2.84M
Increased by 291.66%
EPS This Year
-0.46
from -0.47
EPS Next Year
-0.54
from -0.46
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.9M | 34.3M | 49.7M | ||
| Avg | 2.8M | 11.1M | 26.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 918.2% | 1,106.8% | 346.7% | ||
| Avg | 70.7% | 291.7% | 133.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.38 | -0.37 | 0.08 | ||
| Avg | -0.46 | -0.54 | -0.11 | ||
| Low | -0.58 | -0.72 | -0.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.